REGENERON PHARMACEUTICALS, INC. - 8-K Filing
Regeneron reports Q2 revenue growth of $4.29B (+17%) with Dupixent and Libtayo sales rising sharply, but GAAP net income declines due to manufacturing costs. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $REGN